The Effect of Human Amniotic Membrane Allograft on Functional Recovery After Flexor Tendon Repair

Sponsor
Tampere University (Other)
Overall Status
Terminated
CT.gov ID
NCT02361814
Collaborator
Tampere University Hospital (Other), Central Finland Hospital District (Other)
5
1
1
18.1
0.3

Study Details

Study Description

Brief Summary

The objective of this pilot study is to gain observational insight into potential preventive features of amniotic membrane transplantation in the adhesion formation after flexor tendon repair.

Condition or Disease Intervention/Treatment Phase
  • Procedure: The use of amnionic membrane allograft
N/A

Detailed Description

The treatment of flexor tendon transection consists of surgical apposition of the lacerated tendon ends using non-absorbable sutures. Main complications which result in poor outcome of the tendon repair are the rupture of the tendon apposition or substantial adhesion formation between the two tendons or the tendon and the fibro-osseous canal. Adhesion formation is presumed to be a byproduct of the tendon healing. In the course of last 70 decades, the preventive effects of several pharmacological agents and mechanical barriers on adhesion formation have been investigated with some promising findings. One of the mechanical barriers that has been proposed to be suitable for adhesion prevention is human amniotic membrane allograft. However, there are no clinical studies evaluating the use of amniotic membrane in flexor tendon repair.

This is a pilot study for the forthcoming randomized controlled study. The objectives of the pilot study are: 1) to test the handleability of the human amniotic membrane allograft in flexor tendon sheath reconstruction in conjunction with flexor tendon repair, 2) to elucidate the possible adverse effects related to the use of amniotic membrane in flexor the sheath, and 3) to gain observational insight into potential preventive features of amniotic membrane transplantation in the adhesion formation. The hypothesis of the pilot study is that the application of the human amniotic membrane allograft in tendon sheath reconstruction in flexor tendon injury patients is technically feasible and results in no adverse effects to the patient.

A total of 10 patients with an acute flexor tendon injury will be included in the pilot study. After conventional tendoraphia, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath. The primary outcome measure is total range of movement after 6 months of the surgery.

Study Design

Study Type:
Interventional
Actual Enrollment :
5 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Effect of Human Amniotic Membrane Allograft on Functional Recovery After Flexor Tendon Repair: a Pilot Study
Study Start Date :
Mar 1, 2015
Actual Primary Completion Date :
Sep 1, 2016
Actual Study Completion Date :
Sep 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Amniotic membrane allograft group

After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.

Procedure: The use of amnionic membrane allograft
After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.

Outcome Measures

Primary Outcome Measures

  1. Total range of movement of the injured finger [6 months]

Secondary Outcome Measures

  1. Total range of movement of the injured finger [2, 4, and 8 weeks]

  2. Rupture of the repair [2, 4, 8 weeks, and 6 months]

  3. Postoperative infection [2, 4, 8 weeks, and 6 months]

  4. QuickDASH -score [2, 4, 8 weeks, and 6 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Acute flexor tendon transection in zone 2 in digits 2, 3, 4, or 5 (diagnosed within 1 week after the injury)

  • Age over 18

  • Patient's willingness to participate in the study

Exclusion Criteria:
  • Tendon transection within 8 mm of its distal insertion (requiring reinsertion)

  • Soft-tissue loss, severe crush, fracture, palmar plate injury, patient requiring revascularization

  • Cognitive impairment or other factors (prisoner, military serviceman) which may affect one's decision making

  • Substance abuse

  • Pregnancy

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Tampere Tampere Finland

Sponsors and Collaborators

  • Tampere University
  • Tampere University Hospital
  • Central Finland Hospital District

Investigators

  • Study Chair: Harry Göransson, M.D., Ph.D., Tampere University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Olli Leppänen, Researcher, Tampere University
ClinicalTrials.gov Identifier:
NCT02361814
Other Study ID Numbers:
  • R15002
First Posted:
Feb 12, 2015
Last Update Posted:
Jun 27, 2017
Last Verified:
Jun 1, 2017
Keywords provided by Olli Leppänen, Researcher, Tampere University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 27, 2017